Financial Results

Curaleaf Q3 Results: Strong Margins But $44M Loss, What's Next For Investors?

TerrAscend Expands Footprint Despite Q3 Losses, Can A Move To Ohio Turn The Tide?

Earnings Season Looms Large: Here's When Leading Marijuana Lender And This Cannabis Company Will Report Results

TerrAscend Expands Footprint Despite Q3 Losses, Can A Move To Ohio Turn The Tide?

Earnings Season Looms Large: Here's When Leading Marijuana Lender And This Cannabis Company Will Report Results

Cannabis Giant Green Thumb To Report Q3 Results, Here's What Investors Should Watch For

Billion-Dollar Cannabis Giant Tilray To Report Earnings, Here's What Investors Can Expect

Cannabis Giant Green Thumb To Report Q3 Results, Here's What Investors Should Watch For

Billion-Dollar Cannabis Giant Tilray To Report Earnings, Here's What Investors Can Expect

Irish Biotech Firm GH Research Sees Cash Decline in Q2, Advances Psychedelic Drug Trials

cbdMD Reduces Operating Loss, Reports Positive Net Income For Q3 And 15% YoY Drop In Net Sales

Financial Results Recent News

Blüm Cannabis Co. Reports 111% Increase In Q2 Revenue Following 'Transformative' Sale Of Santa Ana Dispensary

California cannabis company Blüm Holdings, Inc. (OTCQB: BLMH) announced on Thursday its second-quarter financial results for the three months ended June 30, 2024. Patty Chan, the company's CFO called the Blüm's financial results and sale of Blüm Santa Ana "financial milestones" and "the culmination of the transformative journey we began in August 2022."The company's subsidiary Unrivaled Brands, Inc. sold its controlling membership interest in People's First Choice LLC (PFC) to Haven Nectar LLC in June. PFC owns and operates a cannabis retail dispensary campus in Santa Ana, California named Blüm Santa Ana.

Decibel Cannabis Reports 22% YoY Decrease In Q2 Net Revenue, Plans To Benefit With New Product Launches

Decibel Cannabis Company Inc. (TSXV: DB) (OTCQB: DBCCF) reported on Wednesday its unaudited interim financial results for the second quarter ending June 30, 2024. "Decibel has shown good discipline in reducing our current liabilities by ~5mm this quarter," Benjamin Sze, Decibel's CEO, said. "Market share has been challenged but early indications from Qwest relaunch suggest we will regain market share in flower. A continued focus on execution and capital efficiency will serve as the platform for future growth." The company reported net revenue of CA$22.1 million ($16.1 million), down from CA$28.5 million in the prior year's period, representing a 22% year-over-year drop. Its first quarter report published this past April revealed a 16% year-over-year revenue drop to CA$21 million and an adjusted net loss of CA$3.5 million.

IM Cannabis Soars: German Sales Surge 200% In First 3 Months Post-Legalization, Q2 Revenue Up 12% YoY

The company, announced its financial results Wednesday for the second quarter ended June 30, 2024, revealing a 12% year-over-year increase in revenue to CA$14.8 million in the second quarter of 2023. The company also reported a 129% year-over-year increase in IMC Germany sales to CA$3.5 million, making up 24% of the entire company revenue.

MediPharm Q2 Loss Narrows, Adjusted EBITDA Climbs As Gross Profit Improves Nearly 300% YoY

Cannabinoids-focused pharmaceutical company MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) announced on Wednesday financial results for the second quarter ended June 30, 2024, revealing an 8% year-over-year and 6% sequential increase to CA$10.3 million ($7.5 million). "We are very pleased with our Q2 results, showcasing substantial improvements in both revenue and profitability," David Pidduck, the company's CEO, said. "The strategic initiatives implemented, including cost reductions and operational efficiencies, are yielding positive results. We are particularly encouraged by the continued growth in our international sales and the progress in innovation of non-combustible cannabis formats."

Organigram Reports 25% YoY Increase In Q3 Net Revenue, Significant Improvement In Adjusted EBITDA

Cannabis producer Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI) announced on Tuesday results for the third quarter ended June 30, 2024, revealing its net revenue increased 25% year-over-year to CA$41.1 million ($29.9 million). Beena Goldenberg, the company's CEO, praised the revenue milestone. "We are pleased to report a strong third quarter, highlighted by a 25% year-over-year increase in net revenue, and a significant improvement in adjusted EBITDA", Goldenberg said. In May, Organigram announced its second international medical cannabis customer in the UK, Avida Medical, a full-service medical cannabis and special medicines manufacturing business. In June, the company announced a strategic investment aimed at expanding its presence within Germany, one of the burgeoning European cannabis markets.

CBG Producer Willow Biosciences Reports Record Q2 Revenue, Enters Major Pharma Deal Slated To Be Key Driver Of Growth

Willow Biosciences Inc. (TSX: WLLW) (OTCQB: CANSF) reported on Monday its financial and operating results for the three months ended June 30, 2024, reporting significantly higher revenue and reduced costs. "The second quarter was marked by significant pipeline and revenue growth with the addition of the Laurus Labs strategic partnership that includes seven high-value APIs," Dr. Chris Savile, Willow's president and CEO, said. "In addition, the Company further strengthened its balance sheet by launching a private placement in June, which closed after the end of the quarter, and continued on its path to further increase efficiency and reduce costs."

This Cannabis Co With Significant Growth Potential And Other Hot Weed Stocks Soon To Report Earnings, What Investors Need To Know Now

Vext Science, Inc. (CSE: VEXT) (OTCQX: VEXTF), a cannabis operator with vertical operations in Arizona and Ohio, said it will release its financial results for the second quarter ended June 30, 2024, before the market opens on Tuesday, Aug. 20, 2024. A conference call and webcast will take place on the same day at 08:00 am Eastern Time. Auxly Cannabis Group Inc. (TSX: XLY) (OTCQB: CBWTF) will report earnings results for its second quarter ended June 30, 2024, on Thursday, Aug. 15, 2024, before the financial markets open.Cannabinoids-focused MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) will release its second quarter financial results for the period ended June 30, 2024, before markets open on Wednesday, Aug. 14, 2024. A conference call and audio webcast will take place the same day at 8:30 am Eastern Time.

Canopy Growth Q1 Revenue Drops 13% YoY, Reports Wider Net Loss

Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) today announces its financial results for the first quarter ended June 30, 2024.The Canadian cannabis giant reported a record quarter for Canadian medical cannabis, with new revenue surging 20% year-over-year and representing the 6th consecutive quarter of growth. In addition, the company has been ramping up its efforts to expand in the U.S. market via the Canopy USA business unit.

Canadian Cannabis Operations Drive Growth For Village Farms In Q2, Plans To Cash In On Marijuana Program In The Netherlands

Village Farms International, Inc. (NASDAQ: VFF) today reported its financial results for the second quarter that ended June 30, 2024, revealing that total sales grew 19% year-over-year to $92.1 million for the period. The Vancouver-based company said Canadian cannabis grew net sales by 45% and retail branded sales by 35% year-over-year, as well as another quarter of positive adjusted EBITDA and operating cash flow.Michael DeGiglio, president and CEO of Village Farms, said the company is "driving strong momentum in our Canadian Cannabis business."

Cannabis Co. Cresco Lab's Q2 Gross Profit Increases Over 9% YoY, Reports Nearly 7% Drop In Revenue

Cannabis producer and the operator of Sunnyside dispensaries Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) released on Thursday its financial and operating results for the second quarter ended June 30, 2024. "Our Q2 results demonstrate the sustainability of the improvements we've made to the business over the past year with $184 million in revenue at a 29% Adjusted EBITDA margin," Charles Bachtell, CEO of Cresco Labs, said. "It is clear our strategy is working; we are creating the brands consumers love and delivering best-in-class retail operations through Sunnyside."

Highest On Record - Cronos Group Reports 46% YoY Increase In Q2 Net Revenue

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) announced on Tuesday its 2024 second-quarter business results. The company reported $27.8 million in net revenue during the quarter, representing a 46% year-over-year increase. Mike Gorenstein, chairman, president and CEO of Cronos, said that's the "highest quarterly net revenue on record."

IM Cannabis, Organigram And Other Hot Cannabis Stocks Soon To Report Earnings, What Investors Need To Know Now

Medical cannabis company IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC), with operations in Israel and Germany, will report operational and financial results for the second quarter of 2024 ended June 30, 2024, on Wednesday, Aug. 14, 2024. cbdMD, Inc. (NYSE: YCBD) said it will host a conference call at 4:20 pm Eastern Time, on Wednesday, Aug. 14, 2024, to discuss the company's June 30, 2024 third quarter of fiscal 2024 financial results and business progress. Canadian cannabis producer and distributor Entourage Health Corp. (TSX-V: ENTG) (OTCQX: ETRGF) (FSE:4WE) its second quarter 2024 financial results will be released after market close on Monday, Aug. 26, 2024. The company will host a conference call to discuss the results and provide an operational update and recap of achievements on Tuesday, Aug. 27, 2024. Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. will report earnings results for its third quarter fiscal 2024 ended June 30, 2024, on Tuesday, Aug. 13, 2024, before market open. The company will host a conference call to discuss its results with details the same day at 8:00 am Eastern Time.

Trulieve Touts Third Consecutive Quarter Of Revenue Growth, Narrows Q2 Net Loss 97% YoY, Launches Cannabis Sales In Ohio

Trulieve Cannabis Corp. announced on Tuesday its second-quarter results for the three months ended June 30, 2024. The Florida medical cannabis giant reported a 2% quarter-over-quarter and 8% year-over-year increase to $303 million, with 95% of the sum coming from retail sales, driven by higher retail traffic and increased wholesale revenue.

Cannabis Co. C21 Investments Reports Stub Period Revenue Of $4.5M Following $3.5M Deep Roots Harvest Acquisition

Vertically integrated cannabis company C21 Investments Inc. (CSE: CXXI) (OTCQX: CXXIF) announced on Thursday its audited financial statements and management discussion and analysis for its two-month stub fiscal period ended March 31, 2024. The two-month stub period resulted from the company's previously announced change of its fiscal year end from January 31 to March 31. "We are pleased to announce the release of our audited two-month stub period financial statements," CEO and President Sonny Newman said. "This transition from our previous January 31 fiscal year end to a March 31 fiscal year end will better align the company with the reporting schedule of our peers, and better equip our auditors to complete their work promptly moving forward. Our operations continued to perform well in this stub period. Retail sales run rates and margins were comparable to the previous quarter and we remained one of the only positive free cash flow public companies in U.S. cannabis."

Zig-Zag Segment On Sustainable Growth Trajectory, Turning Point CEO Reports 7% YoY Improvement In Adjusted EBITDA, Raises 2024 Guidance

Turning Point Brands, Inc. (NYSE: TPB), a maker of branded consumer products, including alternative smoking accessories and consumables with active ingredients, announced on Thursday financial results for the second quarter ended June 30, 2024. The company said adjusted EBITDA for the quarter came in positive at $27 million, representing a year-over-year improvement of 7%. That said, Turning Point has increased its full-year 2024 adjusted EBITDA guidance to $98 to $102 million. "We were pleased by our second quarter results," Graham Purdy, president and CEO, said. "We achieved our highest quarterly EBITDA since the second quarter of 2021."

California Cannabis Co. StateHouse Reports Flat Revenue YoY In Q1, CEO Touts Expanded Market Presence In FY 2023

California cannabis company StateHouse Holdings Inc. (CSE: STHZ) (OTCQB: STHZF) announced on Thursday its first and fourth-quarter financial results for the three-month periods ended March 31, 2024, and December 31, 2023, respectively as well as full-year fiscal 2023 results.

Scotts Miracle-Gro's Cannabis-Focused Subsidiary Reports 28% YoY Drop In Q3 Net Sales, Reaffirms 2024 Outlook

The Scotts Miracle-Gro Company (NYSE: SMG), the world's largest marketer of branded consumer lawn and garden as well as a leader in indoor and hydroponic growing products, announced on Wednesday its results for the third quarter ended June 29, 2024. Cannabis-focused subsidiary Hawthorne Gardening Company's net sales for the quarter decreased 28%, to $67.7 million, compared to $93.4 million last year. The company said the drop was largely due to the previously announced discontinuation of its third-party distributed brands.

LIfeist Shrinks Net Loss: 49% YoY Drop In Q2 Net Revenue, Plans Move Away From Its Legacy Cannabis Business

Lifeist Wellness Inc. (TSXV: LFST) (FRANKFURT: M5B0) (OTCMKTS: LFSWF), a health-tech company reported on Tuesday its financial results for the three months ended May 31, 2024. The Toronto-based company reported a nearly 50% year-over-year drop in net revenue from continued operations to CA$3.9 million ($2.8 million) in the second quarter of fiscal 2024. Meni Morim, CEO of Lifeist said the company's second-quarter performance "is another clear indication that we must move on from operating our legacy cannabis business segments and find other solutions that have exposure to the broader wellness market."

Greenway's Full-Year Net Loss Widens, Sees Rebound In Q4 As Revenue Increases 9% YoY

Greenway Greenhouse Cannabis Corporation reported on Tuesday its audited annual financial statements for the year ended March 31, 2024. The Kingsville, Ontario, Canada-based company reported a net loss of CA$4.7 million ($3.4 million) for the period, representing an increase from a CA$2.6 million loss in the previous year. "Over the course of the last fiscal year, the cannabis sector has faced intense competition and substantial price compression amid difficult market conditions," Jamie D'Alimonte, CEO of Greenway, said. "Our team began to slowly see prices rebound over the year, and I am happy to report that our revenue in Q4 was up 9% from the previous year. With the total Canadian market continuing to evolve, we are confident that Greenway is one of the best-positioned companies in the cannabis sector."

Medical Marijuana Giant Aurora Will Soon Report Earnings, Here's What Investors Need To Know

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) has scheduled a conference call to discuss the results for its first quarter 2025 on Wednesday, August 7, 2024 at 8:00 am Eastern Time. The Canadian medical cannabis giant said it will report its financial results for the first quarter of 2025 before the opening of markets that same day. CEO Miguel Martin and CFO Simona King will host the conference call and question and answer period. Aurora made headlines last week as it was granted two licenses by the Federal Institute for Drugs and Medical Devices (BfArM) under Germany's new Medical Cannabis Act (MedCanG). The permits granted the company continued domestic cultivation, which has been underway for two years.

Psychedelics Co. Numinus Narrows Loss In Q3, Reports QoQ Decrease In Revenue, Gross Profit

Psychedelics-focused mental health care company Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF), announced on Thursday its third quarter financial results for the three months ended May 31, 2024."In the third quarter of 2024, we continued to make progress on our program to transition Numinus to an operationally lean company prepared to benefit from the anticipated growth in psychedelic therapy. Key to the program is achieving profitability with our existing operations and leveraging our significant experience and expertise to opportunities in the broad market," Payton Nyquvest, Numinus founder and CEO, said.

PharmaCielo Cannabis Co. Narrows Net Loss By 31% YoY In Q1, CEO Says Cost Reduction Efforts Showing Results

PharmaCielo Ltd. (TSXV: PCLO) (OTC Pink: PCLOF) announced on Thursday financial results for the fourth quarter and year ended December 31, 2023, as well as for the first quarter ended March 31, 2024.The Canadian parent of Colombia's cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., also said that effective July 3, 2024, its principal regulator, the Ontario Securities Commission has revoked its failure to file a cease trade order that was issued on May 7, 2024, due to the delay in filing its audited annual consolidated financial statements for the year ended December 31, 2023.

Body and Mind Narrows Loss By 30% YoY In Q3, Doubles Down On Streamlining Operations

Body and Mind Inc. (CSE: BAMM) (OTCQB: BMMJ) announced on Friday its financial results for the third quarter of fiscal year 2024 ended April 30, 2024. Michael Mills, the company's CEO, said BaM is working on streamlining its operations. "We continue to execute our strategy of reducing our footprint and focusing on developing our most valuable assets," he said in a press release. Body and Mind Inc. (CSE: BAMM) (OTCQB: BMMJ) announced on Friday its financial results for the third quarter of fiscal year 2024 ended April 30, 2024. Michael Mills, the company's CEO, said BaM is working on streamlining its operations. "We continue to execute our strategy of reducing our footprint and focusing on developing our most valuable assets," he said in a press release. In Illinois, the company's Markham-based dispensary shows signs of growth, while the building project in the Lynwood store is in its final stages, the company said.